Fenretinide Lipid Matrix
An orally bioavailable powder formulation of a synthetic phenylretinamide analogue of retinol with potential chemopreventive and antineoplastic activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types, including those of the colon, breast, prostate, and neuroblastoma. Independent of RAR activation, this agent also modulates gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS). Compared to the capsule form, the powder contains a mixture of wheat flour, fats, and sugar that may contribute to the enhanced bioavailability of fenretinide. [ ]
Term info
Fenretinide Lipid Matrix
- Fenretinide LXS
- Fenretinide Lipid Matrix
- Fenretinide Lym-X-Sorb
- fenretinide LXS
- fenretinide Lym-X-Sorb
NCIT_C116978, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712
A powdered form of fenretinide that is being studied in the treatment of neuroblastoma. It may be used by the body more easily than the pill form. Fenretinide may cause ceramide (a wax-like substance) to build up in tumor cells and kill them. It is a type of retinoid, which are substances related to vitamin A.
CTRP
Fenretinide Lipid Matrix
http://purl.obolibrary.org/obo/NCIT_C17532
Fenretinide_Lipid_Matrix
468556
468556
Fenretinide Lipid Matrix
Pharmacologic Substance, Organic Chemical
C1831747
C63482
Term relations
- Retinoic Acid Agent
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Retinoic Acid Receptor Activation
- Chemical_Or_Drug_Has_Physiologic_Effect some Apoptosis
- Chemical_Or_Drug_Affects_Gene_Product some Retinoic Acid Receptor
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Cell Differentiation
- Chemical_Or_Drug_Has_Physiologic_Effect some Negative Regulation of Angiogenesis